Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MSH2 inact mut |
| Therapy | Baicalein |
| Indication/Tumor Type | endometrial adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH2 inact mut | endometrial adenocarcinoma | sensitive | Baicalein | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Baicalein selectively induced cell death in an endometrial adenocarcinoma cell line with MSH2 inactivation in culture, and induced apoptosis and tumor shrinkage in MSH2-deficient endometrial adenocarcinoma cell line xenograft models (PMID: 27262172). | 27262172 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27262172) | A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies. | Full reference... |